Nicotinamide (Vitamin B3) for Skin Cancer Prevention

Prepared by your family doctor
Why this matters: If you've had squamous cell carcinoma or actinic keratoses (precancerous spots), nicotinamide can reduce your risk of developing new skin cancers by up to 23%.

What is Nicotinamide?

Nicotinamide is a specific form of Vitamin B3 (also called niacinamide). It works differently from regular niacin and doesn't cause uncomfortable skin flushing. Research shows it helps your skin cells:

Important: You must use nicotinamide or niacinamide — NOT regular niacin or nicotinic acid. These other forms cause flushing and haven't been proven effective for skin cancer prevention.

Recommended Dosage & Instructions

Timing Dose Instructions
Morning 500 mg Take with breakfast to reduce stomach upset
Evening 500 mg Take with dinner
Total Daily 1000 mg Available over-the-counter at most pharmacies

What to Expect

Timing of Benefits

Good news: Clinical studies show a 23% reduction in new squamous cell carcinomas and a 20% reduction in actinic keratoses in high-risk patients.

Side Effects

Nicotinamide is generally very well tolerated. The most common side effects are:

Important Monitoring

Special considerations:
  • Diabetes: Monitor blood sugar levels closely when starting, as nicotinamide can occasionally affect glucose control
  • Kidney disease: Discuss with your doctor before starting — dosage may need adjustment

Regular Follow-Up Care

Action Plan Checklist

Getting Started

Remember: Nicotinamide is a prevention tool, not a cure. It works best as part of a complete sun-safe lifestyle that includes daily sunscreen (SPF 30+), protective clothing, and avoiding peak sun hours.

When to Contact Your Doctor

Call your healthcare provider if you experience:

References

  1. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-1626.
  2. Breglio KF, Geller AC, Braun RP, et al. Nicotinamide for Skin Cancer Chemoprevention: A Retrospective Cohort Study. JAMA Dermatol. 2025;161(11):1140-1147.
  3. Chen AC, Damian DL, Halliday GM. Oral nicotinamide for skin cancer chemoprevention in solid organ transplant recipients (ONTRANS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10415):1815-1824.
  4. Surjana D, Halliday GM, Martin AJ, et al. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol. 2012;132(5):1497-1500.